Chemoprevention of colorectal cancer in inflammatory bowel disease

Abstract

Patients with inflammatory bowel disease are at an increased risk of colorectal cancer when compared to the general population. Chronic inflammation is thought to be the underlying cause, and medications that reduce inflammation have the potential to reduce the risk of colorectal cancer. Areas covered: After conducting a PubMed search for relevant literature, we examined several classes of medications that have been studied as potential chemopreventive agents. These include 5-aminosalicylates, thiopurines, tumor necrosis factor antagonists, ursodeoxycholic acid, NSAIDs, and statins. Expert commentary: While each class of medications has some data to support its use in chemoprevention, the majority of the evidence in each case argues against the routine use of these medications solely for a chemopreventive benefit.

Keywords: 5-aminosalicylates; Crohn’s disease; Inflammatory bowel disease; chemoprevention; colorectal cancer; statins; thiopurines; tumor necrosis factor antagonists; ulcerative colitis; ursodeoxycholic acid.